Continued threat of Haemophilus influenzae type B disease in the UK [23]

Lancet

Volumn 361, Issue 9351, 2003, Pages 90-

  Pushparajah, K ^a   Ramnarayan, P ^a   Maniyar, A ^a   Paget, R ^a   Britto, J ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTERIAL INFECTION; CLINICAL FEATURE; DISEASE COURSE; HAEMOPHILUS INFLUENZAE TYPE B; HOSPITAL ADMISSION; HUMAN; IMMUNIZATION; INCIDENCE; INTENSIVE CARE UNIT; LETTER; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0037417478     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12159-9     Document Type: Letter

References (4)

1. Anon. Continuing surveillance of invasive Haemophilus influenzae disease. CDR Weekly June 2002; 26: 4-5.
2. Heath P.T., Booy R., Griffiths H., et al. Clinical and immunological risk factors associated with Haemophilus influenzae Type b conjugate vaccine. Clin Infect Dis. 31:2000;973-980.
3. Heath P.T., McVernon J. The UK Hib vaccine experience. Arch Dis Child. 86:2002;396-399.
4. Eskola J., Ward J., Dagan R., et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 354:1999;2063-2068.